

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.

Petitioner

v.

WARNER-CHILCOTT COMPANY LLC.

Patent Owner

U.S. Patent No. 7,704,984 to Boissonneault

Issue Date: April 27, 2010

Title: Extended Estrogen Dosing Contraceptive Regimen

Inter Partes Review No. Unassigned

Petition for *Inter Partes* Review of

U.S. Patent No. 7,704,984

Under 35 U.S.C. §§ 311-319 and 37 C.F.R. §§ 42.1-.80, 42.100-.123

Mail Stop "PATENT BOARD"

Patent Trial and Appeal Board

U.S. Patent and Trademark Office

P.O. Box 1450

Alexandria, VA 22313-1450

TABLE OF CONTENTS

	Page
TABLE OF AUTHORITIES	iii
LIST OF EXHIBITS	iv
I. INTRODUCTION AND SUMMARY OF ARGUMENT.....	1
II. MANDATORY NOTICES	4
A. Real Parties-In-Interest (37 C.F.R. § 42.8(b)(1)).....	4
B. Related Matters (37 C.F.R. § 42.8(b)(2)).....	4
C. Identification of Counsel (37 C.F.R. § 42.8(b)(3))	5
D. Service Information (37 C.F.R. § 42.8(b)(4))	6
III. GROUNDS FOR STANDING AND PROCEDURAL STATEMENT	6
IV. STATEMENT OF THE PRECISE RELIEF REQUESTED AND THE REASONS THEREFOR (37 C.F.R. § 42.22(A))	6
V. THRESHOLD REQUIREMENT FOR INTER PARTES REVIEW	6
VI. STATEMENT FOR REASONS FOR THE RELIEF REQUESTED.....	7
A. Prosecution Background of the '984 Patent.....	8
B. Level of Ordinary Skill in the Art.....	12
C. Claim Construction	13
D. Printed Publications Relied On	13

TABLE OF CONTENTS
(continued)

	Page
E. Ground 1: Claims 1-9 of the '984 Patent Are Obvious Over the '868 Publication and the '050 Patent and/or the '394 Patent in further view of Sulak and the General Knowledge in the Art	32
F. Ground 2: Claims 1-9 of the '984 Patent Are Obvious Over the '381 Publication and the '050 Patent and/or the '394 Patent in further view of the Sulak Reference and the General Knowledge in the Art	47
G. Ground 3: Claims 1-9 Are Obvious Over the '490 Patent In View of the '940 Patent and In Further View of the PDR 56 and the General Knowledge in the Art	53
VII. CONCLUSION.....	60

..

TABLE OF AUTHORITIES

	Page(s)
CASES	
<i>Ex parte Gelles</i> , 22 USPQ2d 1318 (B.P.A.I. 1992)	39
<i>In re Aller</i> , 220 F.2d 454 (CCPA 1955)	16
<i>In re Geisler</i> , 116 F.3d 1465 (Fed. Cir. 1997)	40
<i>In re Merck & Co., Inc.</i> , 800 F.2d 1091 (Fed. Cir. 1986)	44
<i>In re Peterson</i> , 315 F.3d 1325 (Fed. Cir. 2003)	16
<i>In re Wertheim</i> , 541 F.2d 257 (CCPA 1976)	40
<i>In re Woodruff</i> , 919 F.2d 1575 (Fed. Cir. 1990)	40
<i>Pfizer v. Apotex</i> , 480 F.3d 1348 (Fed. Cir. 2007)	40

LIST OF EXHIBITS

Ex. No.	Description
Ex. 1001	U.S. Patent No. 7,704,984, titled "Extended Estrogen Dosing Contraceptive Regimen," issued April 27, 2010
Ex. 1002	Prosecution history of U.S. Application Ser. No. 11/112,290, filed April 22, 2005
Ex. 1003	International Publication No. WO 97/41868, titled "Oral Contraceptive," published November 13, 1997
Ex. 1004	U.S. Patent No. 6,667,050, titled "Chewable Oral Contraceptive," issued December 23, 2003
Ex. 1005	U.S. Patent No. 5,552,394, titled "Low Dose Oral Contraceptives with Less Breakthrough Bleeding and Sustained Efficacy," issued September 3, 1996
Ex. 1006	Sulak, P. et al., "Hormone Withdrawal Symptoms in Oral Contraceptive Users," <i>Obstetrics & Gynecology</i> , 95(2):261-266 (2000)
Ex. 1007	United States Patent Application Publ. No. 2003/0139381, titled "Oral Contraceptives to Prevent Pregnancy and Diminish Premenstrual Symptomatology," published July 24, 2003
Ex. 1008	U.S. Patent No. 5,756,490, titled "Pharmaceutical Combination Preparation for Hormonal Contraception," issued May 26, 1998
Ex. 1009	U.S. Patent No. 5,980,940, titled "Pharmaceutical Combination Preparation for Hormonal Contraception," issued November 9, 1999
Ex. 1010	Physicians' Desk Reference (56th ed.) (2002), 2543-2546,

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.